This study in spontaneous hypertensive rats (SHR) was designed to determine whether a greater fall in blood pressure (BP) could be achieved with the combination of an angiotensin-converting enzyme inhibitor (ACE-I) and an AT 1 -receptor blocking drug than with higher doses of either drug alone.
Introduction
The effect of the renin-angiotensin system (RAS) on blood pressure (BP) may be interrupted by inhibiting the conversion of angiotensin I (Ang I) to angiotensin II (Ang II) by angiotensin-converting enzyme inhibitors (ACE-I) or by blocking the effect of Ang II by AT 1 -receptor blocking drugs. 1, 2 Thus, overall it would be expected that the response to these agents should be similar. However, other effects may intervene. ACE-I also prevent the breakdown of bradykinin, which may affect BP causing a fall additional to that resulting from the inhibition of Ang II. 3 Conversely, the high concentration of Ang II with AT 1 -receptor blocking drugs may activate the Ang II type 2 (AT 2 )receptor, which may lower BP. 4, 5 Thus, there could be a differential response to the two classes of drugs. Conversion of Ang I to Ang II, some of which may occur by non-ACE pathways, can take place in tissues, 6 thus supplying Ang II to the AT 1receptor. 7, 8 It is therefore possible that the effects of ACE-I and AT 1 -blocking drugs may be additive.
Previous studies 9 in spontaneously hypertensive rats (SHR) have shown an additional and even synergistic effect of combining relatively low doses of benazeprilat and valsartan, administered by osmotic minipump, but the effect of the com-bination was not directly compared with maximal doses of either drug. This study was designed to study the interaction between captopril, a relatively short acting ACE-I and losartan, an AT 1 -receptor blocking drug in SHR, and whether the response was greater than could be achieved with high-dose monotherapy.
Methods
BP telemeters were inserted as previously described into eight male SHR, weighing approximately 200 g. 10, 11 The rats were allowed to recover for two weeks before the experiments were undertaken. The rats were maintained on standard Australian rat chow, which contains between 0.8 and 1.0% NaCl (w/w).
In the first group of experiments, the rats were divided into two groups of four. One group was given single doses of captopril 0, 5, 10, 20, 40 mg/kg sequentially at 8.00 a.m. by intraperitoneal (i.p.) injection. The doses were given at daily intervals, provided the BP 23-24 hours post-dose had returned to the placebo control level (±5 mmHg). If not at this level, the interval was prolonged for a further 24 hours. The second group was given sequential i.p. injections of losartan 0, 2.5, 5, 10, 20 mg/kg. The doses were given at daily intervals, provided the BP 23-24 hours post-dose had returned to the placebo control level (±5 mmHg). If not at this level the interval before the next injection was prolonged for a further 24 hours.
In the second group of experiments, six of the above eight rats that had had similar falls in BP were selected. The rats were given i.p. injections of placebo, captopril 10 mg/kg, captopril 20 mg/kg, losartan 10 mg/kg, losartan 20 mg/kg and captopril 10 mg/kg + losartan 10 mg/kg in a randomised order at 8.00 a.m. Each rat received all six injections, with three days between each injection.
In the third group of experiments, the same six rats as used in the above experiments were given daily i.p. injections of placebo, captopril 20 mg/kg, losartan 20 mg/kg or captopril 10 mg/kg + losartan 10 mg/kg. The drugs were given in a randomised order, at 8.00 a.m. for one week. The responses presented are the BPs on the 6th and 7th day. There was an interval of three days before they progressed to the next therapeutic regime.
BP was measured as an integrated mean for 10 seconds every 10 minutes. The changes in systolic blood pressure (SBP) in comparison to the randomised placebo were evaluated. The comparisons made were between the mean SBP in the 3rd and 4th hour, the 7th and 8th hour, the 11th and 12th hour and the 23rd and 24th hour post-dose. The statistical comparison was by two-way ANOVA and paired t-testing.
Results

Study 1
Captopril, at all doses used, caused a significant fall in BP (Table 1) . This fall was time-and dose-dependent. The fall in BP in the 3-4 hours post-dose was maximal at the 10 mg/kg dose. Increasing the dose to 20 and 40 mg/kg caused no further fall in SBP, but increased the duration of the hypotensive effect. Since the plateau in the acute response was reached with 10 mg/kg, this dose and the 20 mg/kg dose were used in Study 2. Losartan, at all doses used, caused a significant fall in BP which was time-and dose-dependent. The fall was greater at 7-8 hours than at 3-4 hours post-dose. The maximum fall at 7-8 hours was reached with a dose of 10 mg/kg and there was no further fall with 20 mg/kg, though the duration of the response was extended at the higher dose (Table  2) . Thus, the plateau in acute response was reached with 10 mg/kg and so this dose and the 20 mg/kg dose were used in Study 2.
Study 2
The results of the combined administration of losartan and captopril are shown in Table 3 . The falls in BP in the 3rd and 4th hour, and in the 7th and 8th hour were greatest with the combination of captopril, 10 mg/kg, and losartan 10 mg/kg. In the 3-4 hour post-dose, the BP on the combination was lower (6.5±1.7 mmHg, p<0.01) than with captopril at either 10 or 20 mg/kg. In the 7-8 hours post-dose, the BP on the combination was 12.8±1.9 mmHg lower than on losartan, 10 or 20 mg/kg (p<0.001). In the 3rd and 4th hour postdose with captopril, and at the 7-8 hours postdose with losartan, there was no difference in response between the lower (10 mg) and the higher dose (20 mg) of either drug. Thus, the addition of losartan, 10 mg/kg, to captopril 10 mg/kg, (or vice versa) caused a greater fall in BP than doubling the dose of the drug. The maximum fall in BP with captopril (20 mg/kg) was 4.5±2.0 mmHg greater than the maximum fall with losartan (20 mg/kg) (p=0.05). However, this data needs to be interpreted with caution, as the time at which the maximum falls occurred were different.
Study 3 -Chronic Study
The results of the administration of losartan and captopril over a two-week interval are presented in Table 4 . Overall, the response was similar to Study 2. The combination therapy lowered BP to a greater extent than high-dose monotherapy. The falls at time of peak effect were similar to those in the acute study. The main difference appeared to be that the duration of the response (particularly with captopril) was increased.
Discussion
In SHR, the use of an ACE-I and an AT 1 -receptor 17 PAPER blocking drug in combination caused a greater fall in BP than either of the two drugs as monotherapy at the same or higher doses. 9, 12 This study also indicates the difficulty of examining the interaction between drugs, because of differences in the time of onset of the peak effect of the drug and differences in duration of effect. Thus, comparing 24hour mean pressure or pressure at a set time could lead to spurious results. The valid comparison is at the time of peak effect. In humans, this may make comparisons difficult because of the heterogeneity in responses, whereas the rats used in this study had a relatively homogeneous response. This study differs in its results from the study of Webb et al., 9 in which 1 mg/kg valsartan and 1 mg/kg benazeprilat had more than an additive effect, while in the present study the effect of the combination was less then additive. The doses used in Webb's Study were toward the bottom of the doseresponse curve, and the overall effect did not appear to be greater than that achieved with 10 mg/kg of either drug. The reason for the partially additive effect of the drugs used in this study cannot be fully explained. One reason for the additive effect of captopril on the losartan response may be due to an effect of bradykinin, since captopril also appeared to have a greater maximal effect on BP. We expect that the additive effect may relate also in part to the spatial arrangements of the ACE and the AT 1 -receptor, which makes complete blockade difficult, 13 particularly when coupled with the physiological compensations of a large rise in renin which both alters the kinetics and bypass the blockade. 14 Webb et al. 9 comment on the prolonged effect of the higher doses of valsartan and benazeprilat when therapy was stopped. We have observed a similar response in rats on a reduced (0.2%) NaCl intake, and expect that it is explained in part by angiotensinogen depletion. 11 The results in rats are not directly applicable to humans; the rats used are inbred and have a similar phenotype, whereas humans have a wide variety of phenotypes which may include different activities of alternate conversion pathways, as well as different concentrations of AT 1 -and AT 2 -receptors, which may influence the results. However, the results of Webb at al. 9 suggest that combined use may prevent alteration of the BP response and allow lower doses of both drugs. Additive effects of ACE-I and AT 1 -receptor blocking drugs have been demonstrated in a number of studies 15, 16 and warrant further investigation.
